Published in Hepatitis Weekly, November 13th, 2000
In describing the pharmacokinetics of lamivudine therapy in HBV patients to attendees at the 29th Annual Meeting of the American College of Clinical Pharmacology, held in Chicago, Illinois, Arnold G. Vulto et al. said, "A typical response is a rapid decline with 1-3 log...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.